{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:09:51Z","timestamp":1784660991400,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy: Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.omton.2024.200786","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T17:01:59Z","timestamp":1709139719000},"page":"200786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1607-1386","authenticated-orcid":false,"given":"Emil","family":"Lou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Baca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Gholami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbaya","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy K.","family":"Starr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony F.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Nabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Oberley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Seeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafik","family":"El-Deiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2024.200786_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.omton.2024.200786_bib2","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1470-2045(10)70209-6","article-title":"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer","volume":"12","author":"De Roock","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2024.200786_bib3","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1093\/hmg\/ddh238","article-title":"Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status","volume":"13","author":"Oliveira","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omton.2024.200786_bib4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1476-4598-10-118","article-title":"BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study","volume":"10","author":"Makrodouli","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2024.200786_bib5","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1158\/1078-0432.CCR-22-3655","article-title":"Facts and hopes on RAS inhibitors and cancer immunotherapy","volume":"29","author":"Boumelha","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200786_bib6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.omton.2024.200786_bib7","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200786_bib8","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2024.200786_bib9","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200786_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/14737140.2021.1851201","article-title":"Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy","volume":"21","author":"Roth","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.omton.2024.200786_bib11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12964-020-0517-1","article-title":"Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression","volume":"18","author":"Shang","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.omton.2024.200786_bib12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/JLB.5AB0220-608R","article-title":"Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study","volume":"108","author":"Polidoro","year":"2020","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.omton.2024.200786_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047045","article-title":"The Distribution of Macrophages with a M1 or M2 Phenotype in Relation to Prognosis and the Molecular Characteristics of Colorectal Cancer","volume":"7","author":"Edin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2024.200786_bib14","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1111\/cas.14940","article-title":"Role of tumor-associated macrophages at the invasive front in human colorectal cancer progression","volume":"112","author":"Inagaki","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omton.2024.200786_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030529","article-title":"The Role of Tumor-Associated Neutrophils in Colorectal Cancer","volume":"20","author":"Mizuno","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2024.200786_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2022.104576","article-title":"Neutrophils in the tumor microenvironment and their functional modulation by mesenchymal stromal cells","volume":"379","author":"Zheng","year":"2022","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.omton.2024.200786_bib17","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200786_bib18","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1158\/1535-7163.MCT-20-0462","article-title":"The KRAS(G12C) Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy","volume":"20","author":"Briere","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2024.200786_bib19","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamaoncol.2022.7845","article-title":"A Phase I trial of Regorafenib, Ipilimumab, and Nivolumab in Patients with Microsatellite Stable (MSS) Colorectal Cancer Who Progressed on Prior Chemotherapy","volume":"9","author":"Fakih","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2024.200786_bib20","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200786_bib21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/jamaoncol.2022.7786","article-title":"Immunotherapy Success for Microsatellite Stable Colorectal Cancers-Searching for the Horizon","volume":"9","author":"Lou","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2024.200786_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13059-016-1113-y","article-title":"Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.omton.2024.200786_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3322\/caac.21395","article-title":"Colorectal cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.omton.2024.200786_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.humpath.2016.06.010","article-title":"High frequency of KRAS mutation in early onset colorectal adenocarcinoma: implications for pathogenesis","volume":"56","author":"Watson","year":"2016","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.omton.2024.200786_bib25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-pathol-011110-130235","article-title":"Molecular genetics of colorectal cancer","volume":"6","author":"Fearon","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.omton.2024.200786_bib26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","article-title":"A genetic model for colorectal tumorigenesis","volume":"61","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.omton.2024.200786_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","article-title":"Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors","volume":"6","author":"Lee","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.omton.2024.200786_bib28","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Molecular Therapy: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T09:53:33Z","timestamp":1721642013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329924000286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2950329924000286"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2024.200786","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy: Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2024.200786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"200786"}}